TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03456882

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RNS60
Description: normal saline plus oxigen in nanobubble

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RNS60
Description: normal saline plus oxigen in nanobubble
Study: NCT01144299

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix™/Influsplit SSW®
Description: Single intramuscular dose on Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix™/Influsplit SSW®
Description: Single intramuscular dose on Day 0
Study: NCT05128708

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: combined medial and caudal approach right hemicolectomy open and laparoscopic
Description: resection of right colon cancer by this radical approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: combined medial and caudal approach right hemicolectomy open and laparoscopic
Description: resection of right colon cancer by this radical approach
Study: NCT02133703

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Internet DA
Description: BRCA1/2 carriers randomized to this arm will have access to Internet-based decision support including a preference clarification tool. This intervention is designed to provide education and decision support regarding the available risk management options.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet DA
Description: BRCA1/2 carriers randomized to this arm will have access to Internet-based decision support. This intervention is designed to provide education regarding the available risk management options.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Print DA
Description: BRCA1/2 carriers randomized to this arm will receive print-based decision support materials which include a preference clarification tool. This intervention is designed to provide education and decision support regarding the available risk management options.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Print DA
Description: BRCA1/2 carriers randomized to this arm will receive print education materials designed to provide information regarding the available risk management options.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inconclusive Results DA
Description: Women who receive uninformative BRCA1/2 results randomized to this arm will have access to Internet-based decision support including a preference clarification tool. This intervention is designed to provide education and decision support regarding the available risk management options.
Study: NCT05673798

Intervention type: OTHER
Intervention: initial chemotherapy response
Description: Initial chemotherapy response is the first imaging examination of SCLC patient after starting chemotherapy

Intervention type: OTHER
Intervention: initial chemotherapy response
Description: Initial chemotherapy response is the first imaging examination of SCLC patient after starting chemotherapy
Study: NCT02938715

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: teledermatology feedback
Description: subject provided feedback to continue or discontinue their cream (based on actinic keratoses grading and lesion counting)
Study: NCT03471624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide
Description: Tenofovir alafenamide (TAF) is a new formulation of tenofovir with higher intracellular active drug concentration allowing for dosing of only 25 mg once daily and thus can potentially lower the already low risk of renal toxicity and bone loss with tenofovir disoproxil fumarate (TDF).
Study: NCT01175681

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: remote ischaemic preconditioning
Description: Remote ischaemic preconditioning consisted of three 5-min cycles of right upper arm ischaemia, which was induced by an automated cuff -inflator placed on the right upper arm and inflated to 200 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated. There was a 5- to 10-min interval between completion of the remote ischaemic preconditioning protocol and initiation of bypass.Control patients had a deflated cuff placed on the right upper arm for 30 min.
Study: NCT01306929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pridopidine
Description: 45mg bid
Study: NCT00985829

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: photodynamic therapy
Description: treatment of bcc with 5_ALA cream 20% topical administration once monthly+ photodynamic therapy (red light) 120 j/cm2 once monthly
Study: NCT01870076

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healing Touch

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Healing Touch, Sham

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control, Presence
Study: NCT02434588

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bhattacharjee ring
Description: Insertion of a Bhattacharjee ring to stabilise the pupil during cataract surgery
Study: NCT01143701

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADHD Collaborative
Description: The ADHD Collaborative intervention model includes academic detailing, quality improvement methods, and innovative tools (e.g., web portal) designed to promote and support the systematic use of the AAP guidelines.
Study: NCT00569894

Intervention type: BIOLOGICAL
Intervention: TIV (Injection)
Description: One or two injections of TIV depending on previous status.
Study: NCT02777320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: 1000 mg Paracetamol in 150 ml normal saline given as a slow intravenous infusion over 5 minutes (100 ml of saline is removed before the addition of the 100 ml paracetamol to be the same volume)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 400 mg Ibuprofen in 150 ml normal saline given as a slow intravenous infusion over 5 minutes
Study: NCT00569894

Intervention type: OTHER
Intervention: Unvaccinated Control
Description: no vaccine
Study: NCT03421769

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EA and AMLK
Description: A 7-9mm diameter corneal epithelial tissue will be obtained from the fellow eye using femtosecond laser technology. This epithelial autograft (EA) is then ready for transplantation on the disease eye, following the procedure of allogeneic middle lamellar keratoplasty (AMLK).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LA and AMLK
Description: A 3-clock-hour limbal autograft (LA) will be obtained from the fellow eye. This is then ready for transplantation on the disease eye following the procedure of AMLK.
Study: NCT04136847

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SkinPen Precision
Description: Surgical instrument motors and accessories/attachments/Hydrogel
Study: NCT01700439

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EDWARDS INTUITY valve
Description: Surgical replacement of the aortic valve with the EDWARDS INTUITY valve.
Study: NCT01842503

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GET 73
Description: 300 mg tid on 3 days cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: inactive ingredients capsule
Description: 3 capsules tid on 3 days cycle
Study: NCT01289015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAFT-600 ( naftin 2 % gel )
Description: Topical; applied once daily for two weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical; applied once daily for two weeks
Study: NCT01281410

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Inspiratory Muscle Training with Respifit (5 times per week)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inspiratory muscle training
Description: Inspiratory muscle training with a device named Respifit for patients receiving a hematopoetic stem cell transplantation (till 30 days after their transplantation)
Study: NCT01791907

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured education in carbohydrate counting

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured education in healthy food choices and low glycemic index
Study: NCT03027583

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: 6 weeks daily oral intake of a probiotic strain.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 weeks daily oral intake of placebo.
Study: NCT00039988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate
Description: 20 mg administered subcutaneously daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate
Description: 20 mg administered subcutaneously daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: 2 mg or 4 mg oral capsules taken daily
Study: NCT01859546

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short message service
Description: Short message service reminders on cell phones in improving the compliance of subsequent visits for routine immunization for children
Study: NCT00824837

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Larger pore haemodialysis membrane
Description: Patients receive haemodialysis sessions 3 times a week. They are randomized to start with either treatment A (experimental arm) or treatment B (active comparator arm) and continue for 2 weeks, followed by a 1-week washout period. The patients then cross-over and receive the other treatment (either B or A) for 2 weeks.
Study: NCT00039988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol placebo
Description: Oral placebo capsules will be taken daily
Study: NCT00824837

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Larger pore haemodialysis membrane
Description: Patients receive haemodialysis sessions 3 times a week. They are randomized to start with either treatment A (experimental arm) or treatment B (active comparator arm) and continue for 2 weeks, followed by a 1-week washout period. The patients then cross-over and receive the other treatment (either B or A) for 2 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard haemodialysis membrane
Description: Patients receive haemodialysis sessions 3 times a week. They are randomized to start with either treatment A (experimental arm) or treatment B (active comparator arm) and continue for 2 weeks, followed by a 1-week washout period. The patients then cross-over and receive the other treatment (either B or A) for 2 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard haemodialysis membrane
Description: Patients receive haemodialysis sessions 3 times a week. They are randomized to start with either treatment A (experimental arm) or treatment B (active comparator arm) and continue for 2 weeks, followed by a 1-week washout period. The patients then cross-over and receive the other treatment (either B or A) for 2 weeks.
Study: NCT02079818

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Penumbra Ruby Coil System
Description: The Penumbra Ruby™ Coil is a new generation of detachable coils developed by Penumbra Inc. This coil system is specifically designed for the occlusion of aneurysms and vessels that is equivalent to standard platinum coils. This system consists of: an implantable Coil attached to a Detachment Pusher as well as a Detachment Handle. The Detachment Pusher is comprised of a shaft with a radiopaque positioning marker, a Distal Detachment Tip, and a pull wire. The Detachment Handle is used to detach the Coil Implant from the Detachment Pusher. The Penumbra Ruby Coil is designed for endovascular embolization in the peripheral vasculature. Intended users for this device are physicians who have received appropriate training in interventional radiology and endovascular intervention.
Study: NCT02817399

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation
Description: Electrical stimulation that cause muscle contraction while walking

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuro-muscular electrical stimulation
Description: Electrical stimulation that cause muscle contraction in a stationary position

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active exercises
Description: Subjects will receive training exercise according to ACL reconstruction protocol

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active exercises
Description: Subjects will receive training exercise according to ACL reconstruction protocol
Study: NCT01264601

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Influenza Vaccine
Description: Age appropriate dose of seasonal Trivalent Influenza Vaccine (TIV), either 0.25mL under age 3 or 0.5mL over the age of 3.
Study: NCT01660932

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omega

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omega

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omega
Study: NCT01587079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT003
Description: PT003 MDI administered as two puffs BID for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT003
Description: PT003 MDI administered as two puffs BID for 7 days
Study: NCT03583619

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: APBI
Description: Patients receive radiation to the breast tumor bed to a total dose of 40Gy/10fx/2wks, using intensity-modulated radiation therapy technique.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: WBI
Description: Patients receive radiation to the whole breast to a total dose of 43.5Gy/15fx/3wks, using intensity-modulated radiation therapy technique.
Study: NCT02457104

Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: Patients selected from those undergoing screening colonoscopy. During colonoscopy, stool aspirates and biopsies will be taken from the terminal ileum, cecum, and sigmoid colon.

Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: Patients selected from those undergoing screening colonoscopy. During colonoscopy, stool aspirates and biopsies will be taken from the terminal ileum, cecum, and sigmoid colon.

Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: Patients selected from those undergoing screening colonoscopy. During colonoscopy, stool aspirates and biopsies will be taken from the terminal ileum, cecum, and sigmoid colon.

Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: Patients selected from those undergoing screening colonoscopy. During colonoscopy, stool aspirates and biopsies will be taken from the terminal ileum, cecum, and sigmoid colon.

Intervention type: BEHAVIORAL
Intervention: Weight and diet questionnaire
Description: Brief questionnaire outlining weight history, type and dose of PPI, and diet.

Intervention type: BEHAVIORAL
Intervention: Weight and diet questionnaire
Description: Brief questionnaire outlining weight history, type and dose of PPI, and diet.

Intervention type: BEHAVIORAL
Intervention: Weight and diet questionnaire
Description: Brief questionnaire outlining weight history, type and dose of PPI, and diet.

Intervention type: BEHAVIORAL
Intervention: Weight and diet questionnaire
Description: Brief questionnaire outlining weight history, type and dose of PPI, and diet.
Study: NCT02549599

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chat/Text Program
Description: Participants will receive access to the Chat/Text program on the internet via computer or mobile device. The Chat/Text program involves interactive, immediate, and tailored messages (with pre-determined content) delivered by Chat/Text agents via online chat or mobile phone text. At the conclusion of the session, the participants will receive a combination-baseline and follow-up survey.
Study: NCT01587079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT003
Description: PT003 MDI administered as two puffs BID for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT003
Description: PT003 MDI administered as two puffs BID for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT003
Description: PT003 MDI administered as two puffs BID for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT001
Description: PT001 MDI administered as two puffs BID for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT005
Description: PT005 MDI administered as two puffs BID for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium inhalation powder
Description: Taken as 1 capsule containing 18 µg of Tiotropium via the Handihaler DPI for 7 days
Study: NCT02341378

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TissueGene-C(Low dose)
Description: TissueGene-C at 6.0x10\^6 cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TissueGene-C(High dose)
Description: TissueGene-C at 1.8x10\^7 cells
Study: NCT02661425

Intervention type: OTHER
Intervention: EnteraGam
Description: Serum-derived bovine immunoglobulin/protein isolate (SBI) is the nutritional ingredient in EnteraGam. SBI contains a minimum of 50% immunoglobulin. The protein isolate is a light-colored powder. Each packet contains SBI (5.0 g) and the following inactive ingredients: dextrose (5.0 g) and a trace amount of sunflower lecithin.
Study: NCT00883532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide
Description: budesonide, 0.25 mg/Kg/dose every 8 hours until the infant requires FIO2 \< 30% or is extubated

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: surfactant and air (placebo)
Description: receive surfactant and air as control through endotracheal route
Study: NCT02172859

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: lumiVida™

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03938493

Intervention type: OTHER
Intervention: monitoring of the endotracheal tube cuff
Description: We will enroll adult patients who will undergo endotracheal intubation for general anesthesia of head and neck surgery. The cuff pressure of the endotracheal tube will be monitored continuously during anesthesia. The cuff pressure value will be recorded and analyzed after completing the study.
Study: NCT04592783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihypertensive Agents
Description: Antihypertensive medications will be initialed once BP is at predetermined threshold

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihypertensive Agents
Description: Antihypertensive medications will be initialed once BP is at predetermined threshold
Study: NCT02549599

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Website Content
Description: Participants will be directed to content and information on the Planned Parenthood website. The website contains information on birth control methods, locations of Planned Parenthood health clinics, and on sexual and reproductive health more broadly.

Intervention type: OTHER
Group type: OTHER
Intervention: Delayed Treatment
Description: Participants will receive a baseline survey and be routed to the Planned Parenthood website. No subsequent survey will be administered
Study: NCT02893449

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Social adaptation
Description: Questionnaire to fill-in.~The structured program of preoperative cognitive remediation is divided in 3 parts: one interview with the patient to do a building of the subjective theories (difficulties due to the disease, hope relative to the intervention), a study meeting of the cognitive remediation possibilities and a cognitive remediation meeting with the patient. The spouse will be included in the program.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intensive care management
Description: In this group, the structured program of the SICRPPD group will be replaced by 3 unstructured psychiatric interviews during which patients will be assessed for their perception of the disease and the upcoming surgery. This group will allow to control for the intrinsic effect of the preoperative management independently of the remediation itself.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Deep brain stimulation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Deep brain stimulation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Deep brain stimulation
Study: NCT03174483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic saline
Description: nasal spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Nasal
Description: nasal spray
Study: NCT04418765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Description: Eptinezumab, concentrate for solution for infusion 100 mg/milliliter (mL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Description: Eptinezumab, concentrate for solution for infusion 100 mg/milliliter (mL)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: concentrate for solution for infusion, intravenously
Study: NCT01454778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel in addition to angioplasty, stenting or atherectomy Dosing will be based on the lesion surface area, and will be calculated using the following formula: dose= 22/7 X diameter (mm) X length (mm) X 3 micrograms/mm\^3~Paclitaxel Dosage:~Superficial Femoral/Common Femoral: 2.4 mg/inflation of balloon\* Popliteal: 1.8 mg/inflation of balloon\* Tibial: 1.4 mg/inflation of balloon\*~* not to exceed 10mg total dose
Study: NCT01882283

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tea Treatment Group
Description: This intervention was a crossover trial, during which each patient experienced both placebo and tea treatment arms

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03353727

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orthoptic rehabilitation
Description: Orthoptic rehabilitation using innovative mechanisms (eye tracker and tactile device) for low vision people
Study: NCT02520089

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bone autograft of iliac crest
Description: The investigators will take bone autograft of iliac crest of the patient and then apply into the site of pseudoarthrosis, this graft have osteogenic, osteoinductive and osteoconductive properties
Study: NCT03414580

Intervention type: PROCEDURE
Intervention: Breath sampling for volatile organic compounds
Description: Acquisition of exhaled breath sample in exhaled air to be analysed by gas chromatography-mass spectrometry

Intervention type: PROCEDURE
Intervention: Breath sampling for volatile organic compounds
Description: Acquisition of exhaled breath sample in exhaled air to be analysed by gas chromatography-mass spectrometry

Intervention type: PROCEDURE
Intervention: Breath sampling for volatile organic compounds
Description: Acquisition of exhaled breath sample in exhaled air to be analysed by gas chromatography-mass spectrometry